Karyopharm Therapeutics (NASDAQ:KPTI) and Promedico, a member of the Neopharm Group, have entered into an exclusive distribution agreement for the commercialization of XPOVIO (selinexor), Karyopharm’s lead SINE compound, in Israel and the Palestinian Authority.
Under the terms of the agreement, Karyopharm will
receive certain prespecified payments and is eligible to receive
additional payments if regulatory and commercial milestones are achieved
by Promedico.
KPTI is also eligible to receive double-digit
royalties on future net sales of XPOVIO in the covered territory. In
exchange, Promedico will receive exclusive rights to commercialize
XPOVIO in the covered territory and is responsible for all regulatory
filings and obligations required for registering XPOVIO.
Karyopharm has retained exclusive production rights and will supply finished product for commercial use in the territory.
https://seekingalpha.com/news/3540469-karyopharm-teams-up-promedico-to-commercialize-xpovio
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.